Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables (2020 - 2023)

Historic Receivables for Relay Therapeutics (RLAY) over the last 4 years, with Q3 2023 value amounting to $211000.0.

  • Relay Therapeutics' Receivables fell 9589.57% to $211000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $211000.0, marking a year-over-year decrease of 9589.57%. This contributed to the annual value of $5.2 million for FY2022, which is 564.78% up from last year.
  • Per Relay Therapeutics' latest filing, its Receivables stood at $211000.0 for Q3 2023, which was down 9589.57% from $78000.0 recorded in Q2 2023.
  • Relay Therapeutics' 5-year Receivables high stood at $82.7 million for Q4 2020, and its period low was $78000.0 during Q2 2023.
  • Moreover, its 4-year median value for Receivables was $5.1 million (2021), whereas its average is $11.2 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 1377.46% in 2022, then crashed by 9846.7% in 2023.
  • Relay Therapeutics' Receivables (Quarter) stood at $82.7 million in 2020, then crashed by 94.02% to $4.9 million in 2021, then rose by 5.65% to $5.2 million in 2022, then tumbled by 95.96% to $211000.0 in 2023.
  • Its last three reported values are $211000.0 in Q3 2023, $78000.0 for Q2 2023, and $5.2 million during Q1 2023.